title: Effects of intravenous epinine administration on left ventricular systolic performance, coronary hemodynamics, and circulating catecholamines in patients with heart failure.
abstract: Twenty-six patients with mild to moderate heart failure were studied to determine the effects of epinine infusion (at a rate producing plasma levels similar to those measured after oral administration of 100 mg of the prodrug ibopamine) on left ventricular (LV) function (14 patients), and coronary flow and circulating catecholamines (12 patients). The only significant hemodynamic change at an infusion rate of 0.5 microgram/kg/min was a 9% (p less than 0.05) decrease in systemic vascular resistance (SVR). At an infusion rate of 1 microgram/kg/min (mean free epinine plasma levels 14.3 +/- 3.7 ng/ml), heart rate (HR), dP/dtmax (1,405 +/- 255 to 1,490 +/- 320 mm Hg, NS), (dP/dt)/DP40, and the relaxation rate remained unchanged, but the ejection fraction (EF) increased from 32 to 38% (p less than 0.001), cardiac output (CO) increased, and SVR decreased by 22% (p less than 0.05). In a separate group of 12 patients, epinine infusion at rates of 0.5-1 microgram/kg/min produced no significant changes in coronary blood flow or myocardial oxygen uptake. At these infusion rates, arterial norepinephrine (NE) and dopamine (DA) levels decreased slightly and arterial and coronary sinus epinephrine increased. In conclusion, epinine, at concentrations similar to those achieved during therapeutic use of ibopamine, had negligible effect on myocardial contractility and relaxation rate in heart failure patients. Cardiac pump function was improved by a decrease in SVR rather than by inotropic stimulation. The data also suggest that these low concentrations of epinine may modulate the sympathetic nervous system, but further studies are needed to determine whether this effect could have clinical significance.
authors.affiliation: Department of Physiology and Pharmacology, University of Louvain, Medical School, Brussels, Belgium.
authors.forename: M F
authors.initials: MF
authors.lastname: Rousseau
authors.forename: J
authors.initials: J
authors.lastname: Raigoso
authors.forename: C
authors.initials: C
authors.lastname: van Eyll
authors.forename: H
authors.initials: H
authors.lastname: Van Mechelen
authors.forename: N R
authors.initials: NR
authors.lastname: Musso
authors.forename: G
authors.initials: G
authors.lastname: Lotti
authors.forename: H
authors.initials: H
authors.lastname: Pouleur
mesh_terms: D000328:Adult; D000368:Aged; D002395:Catecholamines / Q000097:blood*; D003326:Coronary Circulation / Q000187:drug effects*; D003846:Deoxyepinephrine / Q000008:administration & dosage* / Q000031:analogs & derivatives / Q000494:pharmacology; D005260:Female; D006333:Heart Failure / Q000188:drug therapy*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D016277:Ventricular Function, Left / Q000187:drug effects*
chemical_list: D002395:Catecholamines; C023487:ibopamine; D003846:Deoxyepinephrine